ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Mithramycin suppresses DNA damage repair via targeting androgen receptor in prostate cancer

Wang, Shan*; Gilbreath, Collin; Kollipara, Rahul K.; Sonavane, Rajni; Huo, Xiaofang; Yenerall, Paul; Das, Amit; Ma, Shihong; Raj, Ganesh, V; Kittler, Ralf*
Cancer Letters2020-9-28DOI: 10.1016/j.canlet.2020.05.027
30阅读
引用收藏
分享

摘要

The dependency of prostate cancer (PCa) growth on androgen receptor (AR) signaling has been harnessed to develop first-line therapies for high-risk localized and metastatic PCa treatment. However, the occurrence of aberrant expression, mutated or splice variants of AR confers resistance to androgen ablation therapy (ADT), radiotherapy or chemotherapy in AR-positive PCa. Therapeutic strategies that effectively inhibit the expression and/or transcriptional activity of full-length AR, mutated AR and AR splice variants have remained elusive. In this study, we report that mithramycin (MTM), an antineoplastic antibiotic, suppresses cell proliferation and exhibits dual inhibitory effects on expression and transcriptional activity of AR and AR splice variants. MTM blocks AR recruitment to its genomic targets by occupying AR enhancers and causes downregulation of AR target genes, which includes key DNA repair factors in DNA damage repair (DDR). We show that MTM significantly impairs DDR and enhances the effectiveness of ionizing radiation or the radiomimetic agent Bleomycin in PCa. Thus, the combination of MTM treatment with RT or radiomimetic agents, such as bleomycin, may present a novel effective therapeutic strategy for patients with high-risk, clinically localized PCa.

学科与关键词

关键词
MithramycinAndrogen receptorDNA damage RepairIonizing radiationBleomycin
相关
加载中…
  • Supraphysiological androgens suppress prostate cancer growth through androgen receptor-mediated DNA damage.
    Chatterjee Payel; Schweizer Michael T; Lucas Jared M; Coleman Ilsa; Nyquist Michael D; Frank Sander B; Tharakan Robin; Mostaghel Elahe; Luo Jun; Pritchard Colin C; Lam Hung Ming; Corey Eva; Antonarakis Emmanuel S; Denmeade Samuel R; Nelson Peter SJournal of Clinical Investigation, 2019, 130.
  • Tautomycin and enzalutamide combination yields synergistic effects on castration-resistant prostate cancer
    Luo, Mayao; Zhang, Yifan; Xu, Zhuofan; Wu, Chenwei; Ye, Yuedian; Liu, Rui*; Lv, Shidong*; Wei, Qiang*Cell Death Discovery, 2022, 8(1): 471.被引 1
  • Integrated analysis reveals FOXA1 and Ku70/Ku80 as targets of ivermectin in prostate cancer
    Lv, Shidong; Wu, Zeyu; Luo, Mayao; Zhang, Yifan; Zhang, Jianqiang; Pascal, Laura E.; Wang, Zhou*; Wei, Qiang*Cell Death & Disease, 2022, 13(9): 754.被引 6
查看全部 →

发表信息

论文状态
公开发表
期刊
Cancer Letters
发表日期
2020-09-28
卷期
第 488 卷
页码
40-49
DOI
10.1016/j.canlet.2020.05.027
语言
ENGLISH
期刊收录
NSL.SCIE
期刊等级
2区
成果收录
SCIE
资助标注
National Cancer Institute of the National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R01CA200787]; CPRIT Scholar in Cancer Research Award of the Cancer Prevention and Research Institute of Texas [R1002]; John L. Roach Endowment in Biomedical Research

作者

  • W

    Wang, Shan (通讯) (第一作者)

  • G

    Gilbreath, Collin

查看全部 10 位作者收起作者
  • K

    Kollipara, Rahul K.

  • S

    Sonavane, Rajni

  • H

    Huo, Xiaofang

  • Y

    Yenerall, Paul

  • D

    Das, Amit

  • M

    Ma, Shihong

  • R

    Raj, Ganesh, V

  • K

    Kittler, Ralf (通讯)

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417